Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 3, Pages 323-334Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2018.1425388
Keywords
Alemtuzumab; multiple sclerosis; depletion; magnetic resonance imaging; T cells lymphocytes; B cells lymphocytes
Ask authors/readers for more resources
Introduction: Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).Areas covered: In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future.Expert opinion: Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available